23536
Bluelight Crew
Hopefully the DEA will take the hint and legalize LSD.
Me too. I also hope to marry Scarlett Johanson tomorrow. Wish me luck!
Hopefully the DEA will take the hint and legalize LSD.







IMO they shouldnt exist point. I see what you mean man. But baniing them mite people start making real acid,or mtie not. GamgbleTell me that when you taking 25X-NBOSH and 2P-4DD. My point is that another chemical which could be even more dangerous now has a market.
I kinda doubt they will stop selling them as acid simply because they are illegal, at least some vendors did a standard blotter print to try and deter it. I'm not defending NBOMEs(personally I found them alright) its just not reasonable to just keep banning shit without legalizing safer, better drugs and educating people more.
^Well I think people would just stay away from NBOMes if they had 2C-X, which is now banned and like I said earlier these probably wouldn't even be used if we could get pure LSD, mushrooms, DMT etc legally.
Yeah they may change the drugs they are buying from china but that doesn't mean they will be safer than the NBOMes, if anything RC's just keep getting worse the more bans that are imposed.
If it was at least sold as nbomes people would know what he fuc kare they takingNot in favour of criminalization by any means, but NOMBes should be scheduled if others are. After GHB, NBOMes have caused the biggest problems in the HR work I've done at festivals.
Statement on Proposed Hydrocodone Reclassification from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research
[10-24-2013] Over the past several years, the U.S. Food and Drug Administration (FDA) has been carefully evaluating and weighing the appropriate use of opioid analgesic drug products. For the millions of American patients experiencing an acute medical need or living with chronic pain, opioids, when prescribed appropriately, can allow patients to manage their pain as well as significantly improve their quality of life.
However, in recent years, the FDA has become increasingly concerned about the abuse and misuse of opioid products, which have sadly reached epidemic proportions in certain parts of the United States. While the value of and access to these drugs has been a consistent source of public debate, the FDA has been challenged with determining how to balance the need to ensure continued access to those patients who rely on continuous pain relief while addressing the ongoing concerns about abuse and misuse.
In 2009, the U.S. Drug Enforcement Administration (DEA) asked the U.S. Department of Health and Human Services (HHS) for a recommendation regarding whether to change the schedule for hydrocodone combination products, such as Vicodin. The proposed change was from Schedule III to Schedule II, which would increase the controls on these products. Due to the unique history of this issue and the tremendous amount of public interest, we are announcing the agency’s intent to recommend to HHS that hydrocodone combination products should be reclassified to a different and more restrictive schedule. This determination comes after a thorough and careful analysis of extensive scientific literature, review of hundreds of public comments on the issue, and several public meetings, during which we received input from a wide range of stakeholders, including patients, health care providers, outside experts, and other government entities.
By early December, FDA plans to submit our formal recommendation package to HHS to reclassify hydrocodone combination products into Schedule II. We anticipate that the National Institute on Drug Abuse (NIDA) will concur with our recommendation. This will begin a process that will lead to a final decision by the DEA on the appropriate scheduling of these products.
Going forward, the agency will continue working with professional organizations, consumer and patient groups, and industry to ensure that prescriber and patient education tools are readily available so that these products are properly prescribed and appropriately used by the patients who need them most.
I imagine dentists will not be able to give you something for pain now, you will have to go to a doctor just to get a few vicodin for a wisdom tooth extraction. Pure bullshit.
SUMMARY: The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to temporarily schedule 10 synthetic cathinones into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act (CSA). The 10 substances are: (1) 4-methyl-N-ethylcathinone ("4-MEC"); (2) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP"); (3) alpha-pyrrolidinopentiophenone ("[alpha]-PVP"); (4) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone"); (5) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone"); (6) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one ("pentylone"); (7) 4-fluoro-N-methylcathinone ("4-FMC"); (8) 3-fluoro-N-methylcathinone ("3-FMC"); (9) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone"); and (10) alpha-pyrrolidinobutiophenone ("[alpha]-PBP"). This action is based on a finding by the Deputy Administrator that the placement of these synthetic cathinones into schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Any final order will be published in the Federal Register and may not be effective prior to February 27, 2014. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I substances under the CSA on the manufacture, distribution, possession, importation, exportation, research, and conduct of instructional activities of these synthetic cathinones.
SUMMARY: The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to temporarily schedule four synthetic cannabinoids into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act (CSA). The substances are: quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 22; QUPIC); quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); and N-(1-amino- 3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB- PINACA). This action is based on a finding by the Deputy Administrator that the placement of these synthetic cannabinoids into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to Schedule I substances under the CSA on the manufacture, distribution, possession, importation, exportation, research, and conduct of instructional activities of these synthetic cannabinoids.